Compare UAA & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAA | DYN |
|---|---|---|
| Founded | 1996 | 1984 |
| Country | United States | United States |
| Employees | 14400 | N/A |
| Industry | Apparel | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | N/A | 2020 |
| Metric | UAA | DYN |
|---|---|---|
| Price | $6.17 | $18.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 14 |
| Target Price | $6.48 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 6.2M | 1.7M |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.13 | $8.25 |
| 52 Week High | $8.15 | $25.00 |
| Indicator | UAA | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 50.39 |
| Support Level | $6.03 | $16.47 |
| Resistance Level | $6.50 | $19.65 |
| Average True Range (ATR) | 0.27 | 0.98 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 14.38 | 42.88 |
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.